Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ZNTL – Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc.
ZNTL
$1.18
Name : Zentalis Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $84,903,240.00
EPSttm : -3.14
finviz dynamic chart for ZNTL
Zentalis Pharmaceuticals, Inc.
$1.18
6.35%
$0.08

Float Short %

10.26

Margin Of Safety %

Put/Call OI Ratio

1.16

EPS Next Q Diff

0.16

EPS Last/This Y

0.12

EPS This/Next Y

0.16

Price

1.2

Target Price

6.28

Analyst Recom

2.11

Performance Q

-34.08

Relative Volume

10.47

Beta

1.62

Ticker: ZNTL




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02ZNTL1.2751.67999.991345
2025-06-03ZNTL1.371.670.001347
2025-06-04ZNTL1.511.660.011351
2025-06-05ZNTL1.461.210.001544
2025-06-06ZNTL1.521.090.001615
2025-06-09ZNTL1.51.060.001641
2025-06-10ZNTL1.631.060.001641
2025-06-11ZNTL1.490.890.001793
2025-06-12ZNTL1.460.890.001793
2025-06-13ZNTL1.350.880.001798
2025-06-16ZNTL1.50.880.001798
2025-06-17ZNTL1.4950.880.001798
2025-06-18ZNTL1.3750.880.001808
2025-06-20ZNTL1.30.840.001779
2025-06-23ZNTL1.2950.840.001779
2025-06-24ZNTL1.3451.160.001509
2025-06-25ZNTL1.311.160.001509
2025-06-26ZNTL1.251.160.001509
2025-06-27ZNTL1.21.160.001509
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02ZNTL1.2858.6- -2.21
2025-06-03ZNTL1.3658.6- -2.21
2025-06-04ZNTL1.5058.6- -2.21
2025-06-05ZNTL1.4758.6- -2.21
2025-06-06ZNTL1.5258.6- -2.21
2025-06-09ZNTL1.4958.6- -2.21
2025-06-10ZNTL1.6458.6- -2.21
2025-06-11ZNTL1.4958.6- -2.21
2025-06-12ZNTL1.4658.6- -2.21
2025-06-13ZNTL1.3458.6- -2.21
2025-06-16ZNTL1.5058.6- -2.21
2025-06-17ZNTL1.4958.6- -2.21
2025-06-18ZNTL1.3858.6- -2.21
2025-06-20ZNTL1.3058.6- -2.21
2025-06-23ZNTL1.3058.6- -2.21
2025-06-24ZNTL1.3558.6- -2.21
2025-06-25ZNTL1.3258.6- -2.21
2025-06-26ZNTL1.2558.6- -2.21
2025-06-27ZNTL1.2058.6- -2.21
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02ZNTL0.67-11.6511.09
2025-06-03ZNTL0.67-11.6511.09
2025-06-04ZNTL0.67-11.6511.09
2025-06-05ZNTL0.67-11.6511.09
2025-06-06ZNTL0.67-11.6511.09
2025-06-09ZNTL0.68-11.6111.06
2025-06-10ZNTL0.68-11.6111.06
2025-06-11ZNTL0.68-11.6110.54
2025-06-12ZNTL0.68-11.6110.54
2025-06-13ZNTL0.68-11.6110.54
2025-06-16ZNTL0.68-11.6110.54
2025-06-17ZNTL0.68-11.6110.54
2025-06-18ZNTL0.68-11.6110.54
2025-06-20ZNTL0.68-11.6110.54
2025-06-23ZNTL0.68-11.6110.54
2025-06-24ZNTL0.67-11.6110.59
2025-06-25ZNTL0.67-11.6110.59
2025-06-26ZNTL0.67-11.6110.26
2025-06-27ZNTL0.67-11.6110.26
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.67

Avg. EPS Est. Current Quarter

-0.51

Avg. EPS Est. Next Quarter

-0.51

Insider Transactions

0.67

Institutional Transactions

-11.61

Beta

1.62

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

17

Growth Score

23

Sentiment Score

22

Actual DrawDown %

98.6

Max Drawdown 5-Year %

-98.8

Target Price

6.28

P/E

Forward P/E

PEG

P/S

3.16

P/B

0.29

P/Free Cash Flow

EPS

-3.15

Average EPS Est. Cur. Y​

-2.21

EPS Next Y. (Est.)

-2.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-834.49

Relative Volume

10.47

Return on Equity vs Sector %

-99.8

Return on Equity vs Industry %

-81.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

Zentalis Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 166
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
stock quote shares ZNTL – Zentalis Pharmaceuticals, Inc. Stock Price stock today
news today ZNTL – Zentalis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ZNTL – Zentalis Pharmaceuticals, Inc. yahoo finance google finance
stock history ZNTL – Zentalis Pharmaceuticals, Inc. invest stock market
stock prices ZNTL premarket after hours
ticker ZNTL fair value insiders trading